Dr. Brian Zambrowicz, Ph.D Has Joined Nuevolution as Director and Senior Scientific Advisor to the Board of Directors
|| Print ||
|Wednesday, 21 May 2014 09:00 (UTC + 2)|
Copenhagen, Denmark, May 21, 2014 / B3C newswire / - Brian Zambrowicz, Ph.D. is one of the co-founders of Lexicon Pharmaceuticals Inc. and has served the company as Executive Vice President and Chief Scientific Officer since 2007. Dr. Zambrowicz has been instrumental in setting the overall scientific direction of the company, including the development of Lexicon's proprietary gene knockout technology and small molecule drug discovery pipeline. Under his direction, Lexicon has knocked out and analyzed nearly 5,000 genes resulting in the identification of more than 100 potential new drug targets. He has been involved in the discovery and development of Lexicon’s portfolio of clinical stage programs, including LX4211, a dual SGLT1 and SGLT2 inhibitor for Type 1 and 2 diabetes, and telotristat etiprate for carcinoid syndrome. Prior to joining Lexicon, he served as a National Institutes of Health postdoctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Zambrowicz received his B.S. in biochemistry from the University of Wisconsin, Madison and his Ph.D. in biochemistry from the University of Washington, Seattle.
Nuevolutions Board of Directors is composed as follows:
“We are very pleased that Brian has decided to join us as Director and Scientific Advisor, said Alex Gouliaev, CEO of Nuevolution A/S. “Brian’s entrepreneurial experience and life science expertise, will strongly support Nuevolution to successfully develop its pipeline within oncology and inflammation”.
Stig Løkke Pedersen, Chairman of Nuevolution A/S said: “Nuevolution A/S has successfully developed and commercialized its Chemetics® technology to a very advanced level, and is progressing its own pre-clinical pipeline. We are convinced that Brian’s expertise in drug discovery and commercialization thereof will add important expertise to the Board of Directors”.
In June 2012, Nuevolution announced a new financing round of € 11 Million to establish an internal pipeline of drug candidates addressing important targets within oncology and inflammation. The lead programs are now in the final optimization stage. In February this year, Nuevolution licensed a small molecule program targeting an undisclosed intracellular protein-protein interaction, to MSD.
Nuevolution’s powerful lead discovery platform is currently being applied against a vast number of therapeutically important targets within oncology and inflammation and several programs are progressed through pre-clinical development by Nuevolution as well as in partnerships to deliver new medication for diseases with an unmet need.
Brian Zambrowicz commented further: “The Nuevolution Chemetics® platform has interested me for many years and I look forward to working with the Nuevolution board and management team to discover novel small molecule drugs using the strengths of this technology.”
In parallel with delivering novel small molecule compounds alone as well as in collaboration with pharmaceutical companies, Nuevolution will continue to form partnerships around its platform technology, similar to the agreement Nuevolution made with Novartis in January this year.
Nuevolution partners its technology with pharmaceutical and biotechnology companies, and has entered into drug discovery agreements with Merck, Novartis, Boehringer Ingelheim, Cancer Research Technology and The Institute of Cancer Research. Furthermore, Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered technology licensing agreements with Nuevolution. Nuevolution participates in a scientific joint venture consortium (Nuevolution, Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals) focusing on GPCR’s, and Nuevolution is currently in the optimization phase for compounds identified under a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and BRIC focusing on epigenetics. Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation and oncology. Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences.
Chemetics® is a registered trademark of Nuevolution.
Chemetics® is a patented technology of Nuevolution: EP1402024, US7,727,713, EP1487978, US7,413,854, EP1756277, EP1608748, US 7,915,201, EP1558744, AU2003273792, CN-ZL20038010476, HKHK1082742, IN213390, IL167531, JP4895608, ZA2005/02624, NZ538993, SG111515, US8,206,901, US7,704,925, EP1957644,EP07114663.3, EP10184311.8, US12/330,709, EP08169346.7, US12/179,323, EP03766117.0, US10/523,006, US10/539,288, US13/179,283, EP09154197.9, AU2011226815, CA2,544,153, CN201210222023.8, EP10183942.1, EP10184069.2, HK11107861.8, HK11107866.3, IL207672, IL207673, IN178/MUMNP/2007, JP2010-226107, JP2013-155967, US11/402,957, US13/455,223, US10/572,644, EP10192716.8, EP10192717.6, US12/095,778, EP09765460.2, US12/999,267, EP11720372.9, IN9924/DELNP/2012, US13/641,588.
Alex Haahr Gouliaev, CEO
Stig Løkke Pedersen, Chairman